The report essentially provides insights on the unmet needs in the pharmaceutical market and potential segments where RNA therapies can prove to be useful. The report also details the market potential that RNA therapies hold in the future. Further, it provides insights into the RNA therapeutics R&D pipeline and the potential promising drugs. The report also contains comprehensive profiles of RNA therapies in late-stage clinical development. The report offers key insights into public and private funding trends in the top markets such as the US, the top five countries in Europe and Japan. The report also elucidates the current competitive landscape of the RNA therapeutics market. Finally, the report deals with key trend analysis on mergers and acquisitions, and licensing agreements involving RNA therapies.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. ( http://www.bharatbook.com/
RNA therapies are biological compounds, which block disease-causing proteins’ biosynthesis. These therapies are a new therapeutic class aimed at treating diseases associated with genetic mutations.
RNA Therapies Can Address the Unmet Needs That Are Prevalent In Chronic Disease Conditions
RNA therapies are the new class of biologic therapies developed to address severe unmet needs that are prevalent in chronic disease conditions such as oncology, autoimmune diseases and CNS disorders. The majority of current therapies approved for these indications either treat symptoms of the disease or retard the rate at which the disease is progressing. Moreover, the conventional therapies are associated with severe side effects such as bone marrow suppression, low platelet counts, sores in the mouth or throat, and nausea and vomiting. RNA therapies have the potential to address these unmet needs.
The prime causative factor for chronic diseases such as oncology and autoimmune diseases is protein overexpression. For example, researchers have studied that synovial tissue in patients with severe chronic rheumatoid arthritis has mutated p53 transcripts. Similarly, metastasis of breast and ovarian cancer is associated with overexpression of AKT2 protein kinase. Therefore, any therapy that can reduce overexpression of these disease-causing proteins will eventually address the potential unmet needs. RNA therapies are the ideal agents that can directly act on the biosynthesis process of these proteins and block their production.
RNA Therapeutics Market Growth, By 2015, Will Be Driven By the Expected Introduction of the Current Late-Stage Development Therapies in Key Disease Areas
Currently six RNA therapies are in late-stage clinical development. They are being evaluated for various indications such as pouchitis, high-grade glioma, high-grade myelodysplastic syndromes (MDS) and advanced melanoma. These are all niche indications with prevalence falling between 10,000 and 40,000. The earliest launch of the first RNA therapy is expected in 2011. The annual cost of treatment with RNA therapies is forecast to lie between $50,000 and $150,000. With a positive note that the RNA therapies in late-stage development reach market with out any problems, the market potential in 2011 is forecast at $0.2 billion. All six RNA therapies are expected to enter the market by 2015 and therefore, the market potential, by 2015, is expected to record $3.5 billion with a CAGR of 100.7% between 2011 and 2015. The unique mechanism of action of RNA therapies and the failure of conventional therapies in effectively treating chronic diseases will be the major factors driving the growth of the RNA therapeutic market potential.
Major Pharmaceutical and Biotechnology Companies are attracted to RNA Therapeutics Sector
Major pharmaceutical and biotechnology companies are attracted to the RNA therapeutics market and they are developing either internal research teams or partnering/acquiring external research units to build capabilities in this potential sector. Roche has set up its own R&D center in Kulmbach, Germany, for research on RNA therapies. Other large pharmaceutical and biotechnology firms such as Merck & Co have acquired RNA therapy-developing companies such as Sirna Therapeutics by paying huge money. Other companies are also adopting a strategic move into the RNA therapeutics market by signing up deals with companies developing RNA therapies. In 2008-2009, the value of total R&D licensing agreements involving RNA therapies was estimated at $3.7 billion. Furthermore, potential funding by venturing capitalists has also driven innovation in RNA therapeutics. Between 2003 and 2008, venture capitalists funded approximately $500 million on small and medium biotechnology companies developing RNA therapies. Major venture capitalists funding RNA therapies developing companies are Oxford Bioscience Partners, Skyline Ventures, LSP and Abingworth, Lilly Ventures, MedSciences Capital, Gimv (Antwerp) and HBM BioVentures Ltd.
RNA Therapeutics Market Is Poised To Become One of the Key Therapeutic Classes in the Pharmaceutical Market by 2020
Research and development on RNA therapies took a giant leap with the discovery of RNA interference technology. Further, significant funding from venture capitalists and investment firms has further persuaded companies to pursue research and development on RNA therapies. As a result, currently, 194 RNA therapy molecules are in research and development. Out of 194 molecules, 77 molecules are targeted at various cancer indications and 21 are targeted at various infectious diseases. More than 50% of RNA therapies in research and development belong to either discovery or preclinical stage indicating a bright future for the RNA therapeutics market. To develop a strong RNA therapies portfolio, major companies are collaborating and acquiring other companies who are into RNA therapeutics research and development. The RNA therapeutics market is poised to overtake other conventional therapies and is expected to become one of the fastest growing therapeutic classes in the pharmaceutical market by 2020.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: http://twitter.com/
# # #
Bharat Book Bureau is the leading business information aggregator providing market research reports and online databases. Bharatbook is also into the business of marketing conferences worldwide and undertakes custom research.